BRPI9710460B8 - composição imunogênica multi-valente e composição de vacina - Google Patents

composição imunogênica multi-valente e composição de vacina

Info

Publication number
BRPI9710460B8
BRPI9710460B8 BRPI9710460A BRPI9710460A BRPI9710460B8 BR PI9710460 B8 BRPI9710460 B8 BR PI9710460B8 BR PI9710460 A BRPI9710460 A BR PI9710460A BR PI9710460 A BRPI9710460 A BR PI9710460A BR PI9710460 B8 BRPI9710460 B8 BR PI9710460B8
Authority
BR
Brazil
Prior art keywords
vaccine
composition
components
toxoid
component
Prior art date
Application number
BRPI9710460A
Other languages
English (en)
Inventor
E D Jackson Gail
Thipphawong John
U L Tan Larry
Barreto Luis
E F Fahim Raafat
Original Assignee
Aventis Pasteur
Connaught Lab
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/672,530 external-priority patent/US6696065B1/en
Application filed by Aventis Pasteur, Connaught Lab, Sanofi Pasteur Ltd filed Critical Aventis Pasteur
Publication of BRPI9710460B1 publication Critical patent/BRPI9710460B1/pt
Publication of BRPI9710460B8 publication Critical patent/BRPI9710460B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"composição imunológica multi-valente e seu uso em vacinas". composição de vacina multi-componente é descrita compreendendo componentes de vacina para coqueluche acelular, toxóide de difteria, toxóide de tétano, e polio vírus inativado. a composição também pose conter um conjugado de um polissacarrídeo capsulado de haemophilus influenzae tipo b e toxóide de tétano, cujo qual pode ser reconstituído de um estado liofilização por outros componentes da vacina. a administração da vacina multi componente resulta não ocasiona diminuição da imunogenicidade de qualquer componente como uma resultante da interferência por outros componentes da vacina.
BRPI9710460A 1996-07-02 1997-07-02 composição imunogênica multi-valente e composição de vacina BRPI9710460B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/672,530 US6696065B1 (en) 1995-05-04 1996-07-02 Acellular pertussis vaccines and methods of preparation thereof
PCT/CA1997/000472 WO1998000167A1 (en) 1996-07-02 1997-07-02 Multivalent dtp-polio vaccines

Publications (2)

Publication Number Publication Date
BRPI9710460B1 BRPI9710460B1 (pt) 2019-02-05
BRPI9710460B8 true BRPI9710460B8 (pt) 2021-05-25

Family

ID=24698948

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9710460A BRPI9710460B8 (pt) 1996-07-02 1997-07-02 composição imunogênica multi-valente e composição de vacina
BR9710460A BR9710460A (pt) 1996-07-02 1997-07-02 Composi-Æo imunolÄgica multi-valente e seu uso em vacinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9710460A BR9710460A (pt) 1996-07-02 1997-07-02 Composi-Æo imunolÄgica multi-valente e seu uso em vacinas

Country Status (20)

Country Link
EP (2) EP1762246A1 (pt)
JP (4) JP3280675B2 (pt)
CN (2) CN101310769B (pt)
AT (1) ATE339965T1 (pt)
AU (1) AU714493B2 (pt)
BR (2) BRPI9710460B8 (pt)
CA (1) CA2259415A1 (pt)
DE (1) DE69736709T2 (pt)
DK (1) DK0914153T3 (pt)
ES (1) ES2271969T3 (pt)
IL (1) IL127847A (pt)
NZ (1) NZ333989A (pt)
PL (1) PL187935B1 (pt)
PT (1) PT914153E (pt)
RO (1) RO120819B1 (pt)
RU (1) RU2194531C2 (pt)
SI (1) SI9720050B (pt)
SK (1) SK283565B6 (pt)
TR (1) TR199802783T2 (pt)
WO (1) WO1998000167A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028750B1 (en) * 1997-09-15 2006-02-01 Sanofi Pasteur MSD Method for preparing multivalent vaccines
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AR041880A1 (es) * 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Composicion inmunogena
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
ES2560452T3 (es) * 2006-09-29 2016-02-19 The Research Foundation For Microbial Diseases Of Osaka University Vacuna de IPV-DPT
WO2009016651A1 (en) * 2007-07-31 2009-02-05 Panacea Biotec Limited Simplified means for obtaining prn from bordetella pertussis
JP5511660B2 (ja) 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
BR112013019675B8 (pt) * 2011-02-04 2022-11-22 Zoetis Services Llc Composições imunogênicas de bordetella bronchiseptica
GB201106225D0 (en) * 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
CN102861330B (zh) * 2012-06-29 2014-10-29 成都欧林生物科技股份有限公司 一种Hib多糖与精制破伤风类毒素偶联工艺
JP6440619B2 (ja) * 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 混合ワクチン用の架橋されていない無細胞百日咳抗原
CN103007264A (zh) * 2012-12-14 2013-04-03 北京民海生物科技有限公司 b型流感嗜血杆菌结合疫苗及其应用
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
PE20151720A1 (es) 2013-03-08 2015-12-10 Crucell Holland Bv Vacuna acelular contra pertussis
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
JP6755243B2 (ja) * 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
CN104707134A (zh) * 2015-03-27 2015-06-17 成都欧林生物科技股份有限公司 一种无细胞百日破联合疫苗及其制备方法
CN108570098B (zh) * 2017-12-29 2021-09-07 武汉生物制品研究所有限责任公司 一种百日咳多种抗原成分的分离纯化方法
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
GB2599572B (en) 2019-05-20 2023-09-20 Soligenix Inc Compositions and methods of manufacturing trivalent filovirus vaccines
CN111000994A (zh) * 2019-12-26 2020-04-14 北京科兴中维生物技术有限公司 一种液体疫苗组合物及其制备方法与应用
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) * 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
IL101692A0 (en) * 1991-05-03 1992-12-30 Amgen Inc Recombinant b oligomer of pertussis toxin
EP2289548A3 (en) * 1992-05-23 2012-08-08 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising hepatitis B surface antigen and other antigens
EP0594950B1 (en) * 1992-10-27 1999-01-27 American Cyanamid Company Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO1997000697A1 (en) * 1995-06-23 1997-01-09 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
AU710538B2 (en) * 1995-05-04 1999-09-23 Connaught Laboratories Limited Acellular pertussis vaccines and methods of preparation thereof
EP1090642B8 (en) * 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein

Also Published As

Publication number Publication date
JP2000504032A (ja) 2000-04-04
BR9710460A (pt) 1999-08-17
CN1228709A (zh) 1999-09-15
CA2259415A1 (en) 1998-01-08
EP1762246A1 (en) 2007-03-14
RU2194531C2 (ru) 2002-12-20
DK0914153T3 (da) 2007-01-29
DE69736709D1 (de) 2006-11-02
JP2006241171A (ja) 2006-09-14
DE69736709T2 (de) 2007-10-04
TR199802783T2 (xx) 1999-03-22
CN100408095C (zh) 2008-08-06
JP2011121981A (ja) 2011-06-23
RO120819B1 (ro) 2006-08-30
CN101310769A (zh) 2008-11-26
WO1998000167A1 (en) 1998-01-08
AU714493B2 (en) 2000-01-06
ATE339965T1 (de) 2006-10-15
EP0914153A1 (en) 1999-05-12
AU3251697A (en) 1998-01-21
IL127847A (en) 2004-06-01
SI9720050A (sl) 1999-12-31
NZ333989A (en) 2000-06-23
IL127847A0 (en) 1999-10-28
JP2002069002A (ja) 2002-03-08
ES2271969T3 (es) 2007-04-16
PL331007A1 (en) 1999-06-21
SI9720050B (en) 2001-12-31
SK181898A3 (en) 2000-05-16
BRPI9710460B1 (pt) 2019-02-05
EP0914153B8 (en) 2006-11-02
PT914153E (pt) 2007-01-31
EP0914153B1 (en) 2006-09-20
JP3280675B2 (ja) 2002-05-13
CN101310769B (zh) 2015-11-25
PL187935B1 (pl) 2004-11-30
SK283565B6 (sk) 2003-09-11

Similar Documents

Publication Publication Date Title
BRPI9710460B8 (pt) composição imunogênica multi-valente e composição de vacina
HU1000593D0 (en) Vaccine compositions
AU4707097A (en) Multivalent vaccines
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
LU91154I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitiqu inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'Haemophilus influenzae type b.
EP0338265A3 (en) Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)